Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CASC3 exon junction complex subunit (CASC3, also known as MLN51, Barentsz, and metastatic lymph node gene 51 protein) is a core component of the exon junction complex (EJC), a multiprotein assembly deposited on spliced mRNAs in the nucleus. CASC3 contributes to post-transcriptional regulation by marking mRNAs for subsequent control mechanisms, chiefly nonsense-mediated mRNA decay (NMD), which eliminates transcripts containing premature termination codons. This protein binds RNA and interacts with other EJC core components; though it shuttles between the nucleus and cytoplasm, its main function is in the cytoplasm, helping to regulate mRNA turnover and translation. CASC3 is not considered a classical drug target or biomarker and is only indirectly associated with disease through its regulatory role in mRNA processing and decay[1][2][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CASC3 exon junction complex subunit (CASC3).